Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients.
Autosomal dominant polycystic kidney disease
High dose
Long term
Tolvaptan
Journal
Case reports in nephrology and dialysis
ISSN: 2296-9705
Titre abrégé: Case Rep Nephrol Dial
Pays: Switzerland
ID NLM: 101636294
Informations de publication
Date de publication:
Historique:
received:
16
10
2019
accepted:
24
01
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
2
4
2020
Statut:
epublish
Résumé
Tolvaptan, a vasopressin V
Identifiants
pubmed: 32232055
doi: 10.1159/000506118
pii: cnd-0010-0009
pmc: PMC7098338
doi:
Types de publication
Case Reports
Langues
eng
Pagination
9-17Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Eiji Ishimura received research grants from Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). The other authors have no conflicts of interest to declare.
Références
Lancet. 2007 Apr 14;369(9569):1287-1301
pubmed: 17434405
Clin J Am Soc Nephrol. 2016 May 6;11(5):803-11
pubmed: 26912543
Clin Exp Nephrol. 2015 Oct;19(5):867-77
pubmed: 25663351
J Am Soc Nephrol. 2014 Jan;25(1):18-32
pubmed: 24335972
Nat Med. 2003 Oct;9(10):1323-6
pubmed: 14502283
Am J Kidney Dis. 2010 Jul;56(1):32-8
pubmed: 20416999
Am J Physiol Renal Physiol. 2011 Nov;301(5):F1005-13
pubmed: 21816754
J Am Soc Nephrol. 2015 Jan;26(1):160-72
pubmed: 24904092
Nephron. 1976;16(1):31-41
pubmed: 1244564
J Am Soc Nephrol. 2018 Oct;29(10):2458-2470
pubmed: 30228150
Clin J Am Soc Nephrol. 2006 Jan;1(1):148-57
pubmed: 17699202
Kidney Int Suppl (2011). 2015 Jun;5(1):15-22
pubmed: 26097781
N Engl J Med. 2012 Dec 20;367(25):2407-18
pubmed: 23121377
N Engl J Med. 2017 Nov 16;377(20):1930-1942
pubmed: 29105594
Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161
pubmed: 30026287